Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.66 Billion JPY | -46.28% |
| 2022 | 14.64 Billion JPY | -12.73% |
| 2021 | 16.77 Billion JPY | 107.64% |
| 2020 | 8.08 Billion JPY | -8.95% |
| 2019 | 8.87 Billion JPY | 341.1% |
| 2018 | 2.01 Billion JPY | -71.07% |
| 2017 | 6.95 Billion JPY | -61.31% |
| 2016 | 17.97 Billion JPY | 120.67% |
| 2015 | 8.14 Billion JPY | 126.12% |
| 2014 | 3.6 Billion JPY | 98.14% |
| 2013 | 1.81 Billion JPY | 11.34% |
| 2012 | 1.63 Billion JPY | 168.41% |
| 2011 | 608.49 Million JPY | -8.63% |
| 2010 | 665.92 Million JPY | -15.92% |
| 2009 | 791.98 Million JPY | 2425.12% |
| 2008 | 31.36 Million JPY | -94.65% |
| 2007 | 586.78 Million JPY | 135.41% |
| 2006 | 249.26 Million JPY | 391.22% |
| 2005 | 50.74 Million JPY | -78.07% |
| 2004 | 231.34 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 4.8 Billion JPY | 97.13% |
| 2024 Q3 | 6.27 Billion JPY | 30.56% |
| 2024 Q1 | 2.43 Billion JPY | -48.92% |
| 2023 Q2 | 1.07 Billion JPY | 25.73% |
| 2023 FY | 7.86 Billion JPY | -46.28% |
| 2023 Q3 | 2.2 Billion JPY | 105.7% |
| 2023 Q1 | 851 Million JPY | -87.38% |
| 2023 Q4 | 4.77 Billion JPY | 116.77% |
| 2022 FY | 14.64 Billion JPY | -12.73% |
| 2022 Q4 | 6.74 Billion JPY | 12.84% |
| 2022 Q3 | 5.97 Billion JPY | 445.66% |
| 2022 Q2 | 1.09 Billion JPY | 31.77% |
| 2022 Q1 | 831 Million JPY | -93.99% |
| 2021 FY | 16.77 Billion JPY | 107.64% |
| 2021 Q4 | 13.82 Billion JPY | 4909.78% |
| 2021 Q3 | 276 Million JPY | -83.72% |
| 2021 Q1 | 981 Million JPY | -76.47% |
| 2021 Q2 | 1.69 Billion JPY | 72.78% |
| 2020 FY | 8.08 Billion JPY | -8.95% |
| 2020 Q1 | 987 Million JPY | -42.28% |
| 2020 Q2 | 1.19 Billion JPY | 21.18% |
| 2020 Q3 | 1.72 Billion JPY | 44.57% |
| 2020 Q4 | 4.16 Billion JPY | 141.12% |
| 2019 Q2 | 1.74 Billion JPY | -40.47% |
| 2019 Q1 | 2.92 Billion JPY | 298.23% |
| 2019 FY | 8.87 Billion JPY | 341.1% |
| 2019 Q3 | 2.5 Billion JPY | 43.79% |
| 2019 Q4 | 1.71 Billion JPY | -31.65% |
| 2018 Q3 | 969 Million JPY | 16.05% |
| 2018 FY | 2.01 Billion JPY | -71.07% |
| 2018 Q2 | 835 Million JPY | 23.16% |
| 2018 Q1 | 678 Million JPY | -29.6% |
| 2018 Q4 | 734 Million JPY | -24.25% |
| 2017 Q1 | 1.78 Billion JPY | 39.41% |
| 2017 FY | 6.95 Billion JPY | -61.31% |
| 2017 Q4 | 963 Million JPY | -61.92% |
| 2017 Q3 | 2.52 Billion JPY | -9.16% |
| 2017 Q2 | 2.78 Billion JPY | 56.14% |
| 2016 FY | 17.97 Billion JPY | 120.67% |
| 2016 Q3 | 756 Million JPY | -94.99% |
| 2016 Q4 | 1.27 Billion JPY | 69.18% |
| 2016 Q2 | 15.08 Billion JPY | 3614.78% |
| 2016 Q1 | 406 Million JPY | -92.19% |
| 2015 FY | 8.14 Billion JPY | 126.12% |
| 2015 Q1 | 2.69 Billion JPY | 599.3% |
| 2015 Q2 | 575 Million JPY | -78.68% |
| 2015 Q3 | 1.96 Billion JPY | 241.74% |
| 2015 Q4 | 5.2 Billion JPY | 164.63% |
| 2014 Q4 | 385.72 Million JPY | 25.74% |
| 2014 Q1 | 151.51 Million JPY | -40.87% |
| 2014 FY | 3.6 Billion JPY | 98.14% |
| 2014 Q2 | 213.08 Million JPY | 40.64% |
| 2014 Q3 | 306.76 Million JPY | 43.96% |
| 2013 Q4 | 256.23 Million JPY | -81.43% |
| 2013 FY | 1.81 Billion JPY | 11.34% |
| 2013 Q2 | 30.91 Million JPY | -46.2% |
| 2013 Q1 | 57.45 Million JPY | -88.64% |
| 2013 Q3 | 1.37 Billion JPY | 4363.7% |
| 2012 Q1 | 1.24 Million JPY | 145.88% |
| 2012 FY | 1.63 Billion JPY | 168.41% |
| 2012 Q2 | 78.16 Million JPY | 6168.08% |
| 2012 Q4 | 505.98 Million JPY | -48.98% |
| 2012 Q3 | 991.64 Million JPY | 1168.69% |
| 2011 Q4 | -2.71 Million JPY | -100.58% |
| 2011 Q3 | 472.42 Million JPY | 243.5% |
| 2011 Q2 | 137.53 Million JPY | 5436.98% |
| 2011 Q1 | -2.57 Million JPY | -131.33% |
| 2011 FY | 608.49 Million JPY | -8.63% |
| 2010 Q1 | -5.18 Million JPY | -111.09% |
| 2010 Q2 | 658.5 Million JPY | 12805.0% |
| 2010 Q3 | 1.78 Million JPY | -99.73% |
| 2010 FY | 665.92 Million JPY | -15.92% |
| 2010 Q4 | 8.22 Million JPY | 362.08% |
| 2009 Q2 | 696.03 Million JPY | 3468.29% |
| 2009 Q3 | 54.39 Million JPY | -92.18% |
| 2009 Q4 | 46.73 Million JPY | -14.09% |
| 2009 FY | 791.98 Million JPY | 2425.12% |
| 2009 Q1 | 19.5 Million JPY | 12817.88% |
| 2008 Q4 | 151 Thousand JPY | -97.45% |
| 2008 FY | 31.36 Million JPY | -94.65% |
| 2008 Q3 | 5.93 Million JPY | 0.0% |
| 2007 FY | 586.78 Million JPY | 135.41% |
| 2006 FY | 249.26 Million JPY | 391.22% |
| 2005 FY | 50.74 Million JPY | -78.07% |
| 2004 FY | 231.34 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | -413.688% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -11933.97% |
| GNI Group Ltd. | 22.43 Billion JPY | 56.917% |
| Linical Co., Ltd. | 3.77 Billion JPY | -155.777% |
| Trans Genic Inc. | 2.24 Billion JPY | -329.652% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -9735.932% |
| Soiken Holdings Inc. | 2.48 Billion JPY | -289.305% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | -647.634% |
| AnGes, Inc. | -3.06 Billion JPY | 415.272% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 5537.828% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -1768.187% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -8609.759% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | -566.209% |
| CanBas Co., Ltd. | -984 Million JPY | 1082.114% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -2367.207% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | -483.522% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -2324.516% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -829.782% |
| PeptiDream Inc. | 17.21 Billion JPY | 43.875% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -31476.54% |
| Ribomic Inc. | -10.5 Million JPY | 92120.568% |
| SanBio Company Limited | -14.5 Million JPY | 66729.895% |
| Healios K.K. | 108 Million JPY | -8848.148% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 2834117.595% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 16466.9% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 639253.439% |
| StemRIM | -44.34 Million JPY | 21890.796% |
| CellSource Co., Ltd. | 3.18 Billion JPY | -203.422% |
| FunPep Company Limited | -680.28 Million JPY | 1520.577% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -13855.235% |
| Stella Pharma Corporation | 217.29 Million JPY | -4347.349% |
| TMS Co., Ltd. | -6.95 Million JPY | 139150.36% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -2972.218% |
| Cuorips Inc. | 9.63 Million JPY | -100242.644% |
| K Pharma,Inc. | 910 Million JPY | -961.978% |
| Takara Bio Inc. | 25.45 Billion JPY | 62.038% |
| ReproCELL Incorporated | 1.1 Billion JPY | -774.79% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | -708.664% |
| StemCell Institute Inc. | 1.57 Billion JPY | -513.244% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | -479.799% |
| CellSeed Inc. | 107.15 Million JPY | -8918.711% |